Endometrial Cancer Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Endometrial Cancer Market Analysis
The endometrial cancer market is expected to register a CAGR of 4.9% during the forecast period.
The COVID-19 pandemic had a moderate impact on the endometrial cancer market due to the reduction in patient visits for diagnosis during the initial phases of the COVID-19 pandemic. As per a study published in January 2022 in PubMed, the corona outbreak correlated with the disruption of screening activities and diagnostic assessments.
Endometrial cancer (EC) is one of the most common gynecological malignancies, and it is often detected at an early stage because it frequently produces symptoms. The data suggested that the COVID-19 pandemic had a significant impact on the characteristics and patterns of care of EC patients. However, post-pandemic, the market is anticipated to witness growth due to a rise in the incidence of endometrial cancer cases, an increase in healthcare expenditure, and technological advancements in endometrial cancer diagnosis and treatment.
For instance, as per a September 2022 update from Cancer Australia, an estimated 3,343 new cases of uterine cancer were diagnosed in Australia in 2022. Similarly, as per a Canadian Cancer Society May 2022 update, an estimated 8,100 Canadian women were likely to be diagnosed with uterine cancer in 2022. As per a May 2021 update from the Mayo Clinic, endometrial cancer begins in the layer of cells that form the lining (endometrium) of the uterus. Endometrial cancer is sometimes called uterine cancer.
Moreover, the rise in awareness programs and collaboration relating to endometrial cancer is anticipated to boost market growth. For instance, in March 2021, Eisai Inc. launched an initiative called 'Spot Her' to end the silence around endometrial cancer and inspire women to listen, advocate, and put their health and the health of other women first. The initiative was conducted in partnership with SHARE Cancer Support (SHARE), Facing Our Risk of Cancer Empowered (FORCE), and Black Health Matters. Moreover, in November 2021, the UNC Lineberger Comprehensive Cancer Center launched the Endometrial Cancer Center of Excellence to advance the scientific understanding of the causes, prevention, and clinical treatment of endometrial cancer and aid researchers in discovering the underlying factors that contribute to why black women in North Carolina are twice as likely to die from endometrial cancer. Such developments spread awareness about endometrial cancer, thereby boosting the demand for the endometrial cancer treatment market.
Factors, such as those mentioned above play a big role in boosting the market growth. But, the high cost associated with the treatment, the adverse effects of the treatment, and the high toxicity of drugs can be a hindrance.
Endometrial Cancer Market Trends
This section covers the major market trends shaping the Endometrial Cancer Market according to our research experts:
The Chemotherapy Segment Expected to Witness a Growth in the Endometrial Cancer Market Over the Forecast Period
The chemotherapy segment is expected to witness growth in the endometrial cancer market owing to the factors such as the increasing prevalence of endometrial cancer requiring chemotherapies and the rise in chemotherapy product developments. Chemotherapy is widely accepted for endometrial cancer since, after surgery, chemotherapy (chemo) with or without radiation therapy is given to help keep cancer from coming back. For instance, as per an article published in February 2022 in PubMed, combining the two drugs (Lenvatinib plus Pembrolizumab) led to longer progression-free survival and overall survival among patients than chemotherapy. Furthermore, per the statistics by the American Cancer Society updated in 2022, there were more than 600,000 endometrial cancer survivors in the United States. As per the same source, around 65,950 new cases of cancer of the body of the uterus (uterine body or corpus) were expected to be diagnosed in 2022. Thus, the demand for chemotherapy may rise with the growing burden of endometrial cancer.
According to the American Cancer Society, endometrial cancer is treated with chemotherapy drugs such doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil), cisplatin, and docetaxel (Taxotere). Furthermore, as per a study published in January 2022 in PubMed, front-line treatment for women with advanced endometrial cancer was firmly established as platinum-based chemotherapy plus taxane. Such studies indicate the efficacy of chemotherapy in the treatment of endometrial cancer. Furthermore, as per an article published in June 2022 by PubMed, over 90% of patients who got adjuvant chemotherapy for endometrial cancer and underwent hysterectomy also received platinum-taxane combination chemotherapy, and nearly 70% of patients who recurred initially were given platinum- or taxane-based therapy. Similarly as per an article published in October 2022 in MDPI, researchers found that the addition of trastuzumab to chemotherapy for high expressers of Her2/neu in endometrial serous carcinoma improved overall survival. Owing to such advantages offered by chemotherapy in endometrial cancer survival, the segment is likely to witness growth over the forecast period.
North America is Anticipated to Witness a Growth in the Endometrial Cancer Market Over the Forecast Period
North America is expected to witness growth in the endometrial cancer market over the forecast period owing to factors such as the rising awareness of the diagnosis of cancer and the country's well-developed healthcare infrastructure. The American Cancer Society estimated about 65,950 new cases of cancer of the body of the uterus (uterine body or corpus) were likely to be diagnosed in the United States. Endometrial cancer affects mainly post-menopausal women. The average age of women diagnosed with endometrial cancer is 60.
Furthermore, there are many clinical studies of endometrial cancer conducted in the studied region. For instance, in July 2022, Canada-based Sunnybrook Health Sciences Centre sponsored a clinical study to assess the effect of megestrol acetate on grade 2 endometrioid endometrial cancer in patients waiting for definitive surgery. Moreover, several market players are engaged in the implementation of strategic initiatives across the region. For instance, in February 2022, Karyopharm Therapeutics Inc., based in the United States, reported positive top-line results from the Phase 3 Selinexor endometrial cancer study, evaluating the efficacy and safety of front-line maintenance therapy using selinexor in patients with advanced or recurrent endometrial cancer.
Endometrial Cancer Industry Overview
The endometrial cancer market is moderately competitive and consists of several major players. Due to the rising prevalence of cancer, there are several products under trial; henceforth, it is expected that a few other smaller players may enter the market. Some of the major players in the market are Bristol-Myers Squibb Company, Pfizer Inc., R-Pharm-US LLC, Elekta AB, and Siemens Healthineers (Varian Medical Systems, Inc.), among others.
Endometrial Cancer Market Leaders
-
Elekta AB
-
Karyopharm Therapeutics
-
Eisai Co., Ltd.
-
GSK plc
-
Siemens Healthineers (Varian Medical Systems, Inc.)
*Disclaimer: Major Players sorted in no particular order
Endometrial Cancer Market News
- In October 2022, Sysmex Corporation reported the approval of an application for a partial change to the manufacturing and marketing approval in Japan of its gene amplification reagent LYNOAMP CK19 marketed as a lymph node metastasis test reagent for breast cancer, colorectal cancer, gastric cancer, and non-small cell lung cancer, expanding its amplification to cervical cancer and endometrial cancer.
- In March 2022, the United States Food and Drug Administration (FDA) approved KEYTRUDA, Merck's anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test. These patients had disease progression following prior systemic therapy in any setting and were not candidates for curative surgery or radiation.
Endometrial Cancer Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Awareness about Uterine Diseases and Available Therapies
4.2.2 Increase in Prevalence of Endometrial Cancer Cases
4.2.3 Innovation in Drug Development and Subsequent Technological Advancements
4.3 Market Restraints
4.3.1 High Cost Associated with the Treatment
4.3.2 Adverse Effects of the Treatment and High Toxicity of Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Type of Cancer
5.1.1 Endometrial Carcinoma
5.1.1.1 Adenocarcinoma
5.1.1.2 Carcinosarcoma
5.1.1.3 Squamous Cell Carcinoma
5.1.1.4 Other Types of Cancer
5.1.2 Uterine Sarcomas
5.2 By Type of Therapy
5.2.1 Immunotherapy
5.2.2 Radiation Therapy
5.2.3 Chemotherapy
5.2.4 Other Types of Therapies
5.3 By Diagnosis Method
5.3.1 Biopsy
5.3.2 Pelvic Ultrasound
5.3.3 Hysteroscopy
5.3.4 CT Scan
5.3.5 Other Diagnosis Methods
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck KGaA
6.1.2 Eisai Co. Ltd
6.1.3 Novartis AG
6.1.4 Elekta AB
6.1.5 Siemens Healthineers (Varian Medical Systems, Inc.)
6.1.6 GSK plc
6.1.7 Karyopharm Therapeutics
6.1.8 Takeda Pharmaceutical Company Limited
6.1.9 Bristol Myers Squibb
6.1.10 F. Hoffmann-La Roche AG
6.1.11 Context Therapeutics
6.1.12 AstraZeneca PLC
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Endometrial Cancer Industry Segmentation
As per the scope of this report, endometrial cancer is a malignancy that develops in the layers of the cells that form the endometrium, the lining of the uterus. Women with high blood pressure, diabetes, or breast cancer are at a greater risk of getting endometrial cancer.
The endometrial cancer market is segmented by Type of Cancer (Endometrial Carcinoma (Adenocarcinoma, Carcinosarcoma, Squamous Cell Carcinoma, Other Types of Cancer), Uterine Sarcomas), Type of Therapy (Immunotherapy, Radiation Therapy, Chemotherapy, and Other Types of Therapies), Diagnosis Method (Biopsy, Pelvic Ultrasound, Hysteroscopy, CT Scan, and Other Diagnosis Methods), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the market sizes and forecasts in terms of value (USD million) for the above segments.
| By Type of Cancer | ||||||
| ||||||
| Uterine Sarcomas |
| By Type of Therapy | |
| Immunotherapy | |
| Radiation Therapy | |
| Chemotherapy | |
| Other Types of Therapies |
| By Diagnosis Method | |
| Biopsy | |
| Pelvic Ultrasound | |
| Hysteroscopy | |
| CT Scan | |
| Other Diagnosis Methods |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Endometrial Cancer Market Research FAQs
What is the current Global Endometrial Cancer Market size?
The Global Endometrial Cancer Market is projected to register a CAGR of 4.90% during the forecast period (2024-2029)
Who are the key players in Global Endometrial Cancer Market?
Elekta AB, Karyopharm Therapeutics, Eisai Co., Ltd., GSK plc and Siemens Healthineers (Varian Medical Systems, Inc.) are the major companies operating in the Global Endometrial Cancer Market.
Which is the fastest growing region in Global Endometrial Cancer Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Endometrial Cancer Market?
In 2024, the North America accounts for the largest market share in Global Endometrial Cancer Market.
What years does this Global Endometrial Cancer Market cover?
The report covers the Global Endometrial Cancer Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Endometrial Cancer Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Endometrial Cancer Treatment Industry Report
Statistics for the 2024 Endometrial Cancer Treatment market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Endometrial Cancer Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Endometrial Cancer Treatment Market Report Snapshots
